Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peroxisomal biogenesis factor 13 (PEX13) is an integral peroxisomal membrane protein and a core component of the peroxisomal protein import machinery[3][2]. It interacts with the type 1 peroxisomal targeting signal receptor (PEX5) via an SH3 domain and forms the PEX13–PEX14 docking complex, which is essential for the import of peroxisomal matrix proteins[3]. PEX13 is also required for selective autophagy processes, such as mitophagy and virophagy, independently of general autophagy pathways[2][5]. Mutations in PEX13 cause peroxisome biogenesis disorders of the Zellweger syndrome spectrum, characterized by impaired peroxisomal protein import, leading to multi-organ, especially neurological, abnormalities and neonatal lethality[2][3][1][5]. The role of PEX13 is specific to peroxisome assembly and import, and it is not currently considered a direct therapeutic target or receptor in drug development[3][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peroxisomal biogenesis factor 13 (PEX13).